TOP TEN perturbations for Q14573 (Homo sapiens)

Organism: Homo sapiens
Gene: Q14573
Selected probe(set): 201189_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q14573 (201189_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

glioma study 16 (LN-215) / normal astrocyte sample

Relative Expression (log2-ratio):3.7197428
Number of Samples:2 / 3
Experimental glioma study 16 (LN-215)
Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

diazinon study 1 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):3.5491276
Number of Samples:3 / 19
Experimental diazinon study 1 (48h)
HepG2 cells exposed to 250μM diazinon in DMSO solvent for 48 hours. ATCvet code:
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.

stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):-3.2862396
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):3.2412586
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-3.239996
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

small cell lung cancer study 4 (1. gen. PDX) / small cell lung cancer study 4 (XCL from PDX)

Relative Expression (log2-ratio):3.1618233
Number of Samples:4 / 3
Experimental small cell lung cancer study 4 (1. gen. PDX)
A small cell lung cancer (SCLC) primary xenograft tumor tissue samples derived from three chemo-naive patients (LX22; LX33 and LX36; first generation-1. gen.). The discarded tissue obtained during bronchoscopy of SCLC patients was used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice (NOD/SCID). The mice were sacrificed when the P0 tumors reached 1cm in diameter.
Control small cell lung cancer study 4 (XCL from PDX)
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) patient derived xenografts (PDX). The discarded tissue from three chemo-naive patients (LX22; LX33 and LX35) was obtained during bronchoscopy and used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice. The mice were sacrificed when the P0 tumors reached 1cm in diameter. Obtained cells were used for conventional cell culture cultivation.

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):3.0756197
Number of Samples:2 / 3
Experimental glioma study 16 (LN-229)
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

DDT study 1 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):2.9310684
Number of Samples:3 / 19
Experimental DDT study 1 (48h)
HepG2 cells exposed to 80μM 1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane (DDT) in DMSO solvent for 48 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.

retina pigment epithelium study 2 (fetal) / retina pigment epithelium study 1 (fetal)

Relative Expression (log2-ratio):2.9029894
Number of Samples:12 / 6
Experimental retina pigment epithelium study 2 (fetal)
Human cultured fetal retina pigment epithelium samples obtained at gestation age between week 16-18.
Control retina pigment epithelium study 1 (fetal)
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):2.8713226
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).